{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T01:55:15Z","timestamp":1777859715952,"version":"3.51.4"},"reference-count":56,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[2020,9,24]],"date-time":"2020-09-24T00:00:00Z","timestamp":1600905600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmacy Practice"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:p>Osteoporosis is a growing epidemic that leads to significant morbidity and mortality among the elderly population due to associated fractures that lead to disabilities and reduced quality of life. Bisphosphonates are well-established as a first-line and cost-effective treatment for osteoporosis. Unfortunately, clinicians are often uncertain as to how to select treatments when bisphosphonates are ineffective as initial treatment or contraindicated. Romosozumab and abaloparatide are 2 alternative agents that have been recently FDA approved for the treatment of osteoporosis in postmenopausal women at high risk for fracture or patients who have failed or are intolerant to other osteoporosis therapies. Currently, the National Osteoporosis Foundation (NOF) has no formal recommendations in regard to these 2 novel agents. The purpose of this review is to help guide pharmacists on how to ensure appropriate utilization of these 2 novel bone-forming agents as potential alternatives to bisphosphonate therapy by providing evidence-based recommendations according to the current literature and key counseling points.<\/jats:p>","DOI":"10.1177\/0897190020961227","type":"journal-article","created":{"date-parts":[[2020,9,24]],"date-time":"2020-09-24T07:01:24Z","timestamp":1600930884000},"page":"952-961","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":2,"title":["The Role of Novel Bone Forming Agents in the Treatment of Osteoporosis"],"prefix":"10.1177","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6389-4465","authenticated-orcid":false,"given":"Hansita B.","family":"Patel","sequence":"first","affiliation":[{"name":"Department of Pharmacy Practice, University of the Incarnate Word Feik School of Pharmacy, San Antonio, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lynsie J.","family":"Lyerly","sequence":"additional","affiliation":[{"name":"University of the Incarnate Word Feik School of Pharmacy, San Antonio, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheryl K.","family":"Horlen","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, University of the Incarnate Word Feik School of Pharmacy, San Antonio, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2020,9,24]]},"reference":[{"key":"bibr1-0897190020961227","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.061113"},{"key":"bibr2-0897190020961227","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2474-12-105"},{"key":"bibr3-0897190020961227","doi-asserted-by":"publisher","DOI":"10.1007\/s00223-012-9666-6"},{"key":"bibr4-0897190020961227","doi-asserted-by":"publisher","DOI":"10.1007\/PL00004148"},{"key":"bibr5-0897190020961227","doi-asserted-by":"publisher","DOI":"10.1007\/BF01623184"},{"key":"bibr6-0897190020961227","doi-asserted-by":"publisher","DOI":"10.1053\/berh.2002.0264"},{"key":"bibr7-0897190020961227","doi-asserted-by":"publisher","DOI":"10.1016\/j.anr.2017.05.010"},{"key":"bibr8-0897190020961227","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2474-15-334"},{"key":"bibr9-0897190020961227","doi-asserted-by":"publisher","DOI":"10.1258\/rsmsmj.52.1.13"},{"key":"bibr10-0897190020961227","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-011-1661-7"},{"key":"bibr11-0897190020961227","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-014-2794-2"},{"key":"bibr12-0897190020961227","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-014-2738-x"},{"key":"bibr13-0897190020961227","doi-asserted-by":"publisher","DOI":"10.1097\/01.grf.0000437016.19989.61"},{"key":"bibr14-0897190020961227","doi-asserted-by":"crossref","unstructured":"Cosman F, Crittenden DB, Adachi JD, et al. Romosozumab treatment in postmenopausal women with osteoporosis. New Engl J Med. 2016;375(6):1532\u20131543. Accessed October 21, 2019. https:\/\/www.nejm.org\/doi\/suppl\/10.1056\/NEJMoa1607948\/suppl_file\/nejmoa1607948_appendix.pdf","DOI":"10.1056\/NEJMoa1607948"},{"key":"bibr15-0897190020961227","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1708322"},{"key":"bibr16-0897190020961227","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.11136"},{"key":"bibr17-0897190020961227","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200105103441904"},{"key":"bibr18-0897190020961227","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0809493"},{"key":"bibr19-0897190020961227","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(00)00490-3"},{"key":"bibr20-0897190020961227","doi-asserted-by":"publisher","DOI":"10.1001\/jama.282.7.637"},{"key":"bibr21-0897190020961227","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)07088-2"},{"key":"bibr22-0897190020961227","doi-asserted-by":"publisher","DOI":"10.1359\/JBMR.040325"},{"key":"bibr23-0897190020961227","doi-asserted-by":"publisher","DOI":"10.1001\/jama.282.14.1344"},{"key":"bibr24-0897190020961227","doi-asserted-by":"publisher","DOI":"10.1185\/030079904125003683"},{"key":"bibr25-0897190020961227","unstructured":"Amgen, Inc. Evenity\u00ae (Romosozumab-Aqqg) [Package Insert]. US Food and Drug Administration website. Published 2019. Updated April 2019. Accessed October 21, 2019. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/761062s000lbl.pdf"},{"key":"bibr26-0897190020961227","unstructured":"Radius Health, Inc. Tymlos\u00ae (Abaloparatide) [Package Insert]. US Food and Drug Administration website. Published 2017. Updated October 2018. Accessed October 21, 2019. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/208743s003lbl.pdf"},{"key":"bibr27-0897190020961227","unstructured":"Eli Lilly and Company. Forteo\n                      \u00ae\n                      (Teriparatide) [Package Insert]. US Food and Drug Administration website. Published 2002. Updated October 2019. Accessed October 21, 2019. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/021318s052lbl.pdf"},{"key":"bibr28-0897190020961227","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2017.03.006"},{"key":"bibr29-0897190020961227","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2018-00163"},{"key":"bibr30-0897190020961227","unstructured":"Amgen, Inc. Prolia\u00ae (Denosumab) [Package Insert]. US Food and Drug Administration website. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/125320s202lbl.pdf. Published 2010. Revised July 2019. Accessed October 21, 2019."},{"key":"bibr31-0897190020961227","doi-asserted-by":"publisher","DOI":"10.4158\/GL-2020-0524SUPPL"},{"key":"bibr32-0897190020961227","unstructured":"Mylan. Miacalcin\u00ae (Calcitonin-Salmon, Nasal Spray) [Package Insert]. US Food and Drug Administration website. Published 1975. Revised September 2017. Accessed October 21, 2019. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/020313s036lbl.pdf"},{"key":"bibr33-0897190020961227","unstructured":"Mylan. Miacalcin\u00ae (Calcitonin-Salmon, Injection) [Package Insert]. US Food and Drug Administration website. Published 1975. Revised September 2017. Accessed October 21, 2019. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/017808s037lbl.pdf"},{"key":"bibr34-0897190020961227","unstructured":"Eli Lilly and Company. Evista\u00ae (Raloxifene Hydrochloride) [Package Insert]. US Food and Drug Administration website. Published 1977. Revised June 2018. Accessed October 21, 2019. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/020815s034lbl.pdf"},{"key":"bibr35-0897190020961227","unstructured":"Roche Therapeutics Inc. Boniva\u00ae (Ibandronate Sodium, Tablets) [Package Insert]. US Food and Drug Administration website. Published 2003. Revised December 2016. Accessed October 21, 2019. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/021455s021lbl.pdf"},{"key":"bibr36-0897190020961227","unstructured":"Merck & Co., Inc. Fosamax\u00ae (Alendaronate Sodium) [Package Insert]. US Food and Drug Administration website. Published 1995. Revised August 2019. Accessed October 21, 2019. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/020560s070lbl.pdf"},{"key":"bibr37-0897190020961227","unstructured":"Warner Chilcott Company LLC. Actonel\u00ae (Risedronate Sodium) [Package Insert].US Food and Drug Administration website. Published 1998. Revised March 2015. Accessed October 21, 2019. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/020835s048lbl.pdf"},{"key":"bibr38-0897190020961227","unstructured":"Norwich Pharmaceuticals, Inc. Atelvia\u00ae (Risedronate Sodium) [Package Insert]. US Food and Drug Administration website. Published 1998. Revised March 2015. Accessed October 21, 2019. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/022560s007lbl.pdf"},{"key":"bibr39-0897190020961227","unstructured":"Genentech, Inc. Boniva\u00ae (Ibandronate Sodium, Injection) [Package Insert]. US Food and Drug Administration website. Published 2003. Updated December 2016. Accessed October 21, 2019. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/021858s022lbl.pdf"},{"key":"bibr40-0897190020961227","unstructured":"Novartis Pharmaceuticals Corporation. Reclast\u00ae (Zoledronic Acid) [Package Insert]. US Food and Drug Administration website. Published 2001. Revised July 2017. Accessed October 21, 2019. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/021817s027lbl.pdf"},{"key":"bibr41-0897190020961227","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocd.2011.03.004"},{"key":"bibr42-0897190020961227","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S3552"},{"key":"bibr43-0897190020961227","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2010-2704"},{"key":"bibr44-0897190020961227","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.14854"},{"key":"bibr45-0897190020961227","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.102.18.2284"},{"key":"bibr46-0897190020961227","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-018-0087-0"},{"key":"bibr47-0897190020961227","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S127568"},{"key":"bibr48-0897190020961227","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1305224"},{"key":"bibr49-0897190020961227","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.173"},{"key":"bibr50-0897190020961227","doi-asserted-by":"publisher","DOI":"10.1210\/en.2015-1726"},{"key":"bibr51-0897190020961227","doi-asserted-by":"publisher","DOI":"10.1177\/1060028017748649"},{"key":"bibr52-0897190020961227","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.2991"},{"issue":"6","key":"bibr53-0897190020961227","first-page":"2129","volume":"85","author":"Rittmaster RS","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"bibr54-0897190020961227","volume-title":"RED BOOK Online. Micromedex Healthcare Series [Database Online]","author":"Active ingredient: Abaloparatide","year":"2020"},{"key":"bibr55-0897190020961227","volume-title":"RED BOOK Online. Micromedex Healthcare Series [Database Online]","author":"Active ingredient: Teriparatide","year":"2020"},{"key":"bibr56-0897190020961227","volume-title":"RED BOOK Online. Micromedex Healthcare Series [Database Online]","author":"Active ingredient: Romosozumab","year":"2020"}],"container-title":["Journal of Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0897190020961227","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/0897190020961227","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0897190020961227","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:36:16Z","timestamp":1777509376000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/0897190020961227"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,24]]},"references-count":56,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["10.1177\/0897190020961227"],"URL":"https:\/\/doi.org\/10.1177\/0897190020961227","relation":{},"ISSN":["0897-1900","1531-1937"],"issn-type":[{"value":"0897-1900","type":"print"},{"value":"1531-1937","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,24]]}}}